-
2
-
-
84888784541
-
Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage
-
COI: 1:CAS:528:DC%2BC2cXhtVykt74%3D, PID: 24269967
-
Nakamura H, Etrych T, Chytil P et al (2014) Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage. J Control Release 174:81–87
-
(2014)
J Control Release
, vol.174
, pp. 81-87
-
-
Nakamura, H.1
Etrych, T.2
Chytil, P.3
-
3
-
-
84873268296
-
The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo
-
COI: 1:CAS:528:DC%2BC38Xhs1CjsbnI, PID: 23088862
-
Maeda H, Nakamura H, Fang J (2013) The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 65:71–79
-
(2013)
Adv Drug Deliv Rev
, vol.65
, pp. 71-79
-
-
Maeda, H.1
Nakamura, H.2
Fang, J.3
-
4
-
-
84860777658
-
Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting
-
COI: 1:CAS:528:DC%2BC38Xms12iurk%3D, PID: 22450535
-
Maeda H (2012) Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc Jpn Acad Ser B Phys Biol Sci 88:53–71
-
(2012)
Proc Jpn Acad Ser B Phys Biol Sci
, vol.88
, pp. 53-71
-
-
Maeda, H.1
-
5
-
-
84919460238
-
Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls
-
COI: 1:CAS:528:DC%2BC2cXitFahtbfO, PID: 25425260
-
Nakamura H, Fang J, Maeda H (2015) Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls. Expert Opin Drug Deliv 12:53–64
-
(2015)
Expert Opin Drug Deliv
, vol.12
, pp. 53-64
-
-
Nakamura, H.1
Fang, J.2
Maeda, H.3
-
6
-
-
48349107149
-
Tumor-targeted nanomedicines: principles and practice
-
COI: 1:CAS:528:DC%2BD1cXptFSntr0%3D, PID: 18648371
-
Lammers T, Hennink WE, Storm G (2008) Tumor-targeted nanomedicines: principles and practice. Br J Cancer 99:392–397
-
(2008)
Br J Cancer
, vol.99
, pp. 392-397
-
-
Lammers, T.1
Hennink, W.E.2
Storm, G.3
-
7
-
-
51449104513
-
Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy
-
COI: 1:CAS:528:DC%2BD1cXhtV2jurrF, PID: 19238631
-
Lammers T, Subr V, Peschke P et al (2008) Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy. Br J Cancer 99:900–910
-
(2008)
Br J Cancer
, vol.99
, pp. 900-910
-
-
Lammers, T.1
Subr, V.2
Peschke, P.3
-
8
-
-
84925785111
-
Synthesis and therapeutic effect of styrene-maleic acid copolymer conjugated pirarubicin
-
COI: 1:CAS:528:DC%2BC2MXkvVOqtLw%3D, PID: 25529761
-
Tsukigawa K, Liao L, Nakamura H et al (2015) Synthesis and therapeutic effect of styrene-maleic acid copolymer conjugated pirarubicin. Cancer Sci 106:270–278
-
(2015)
Cancer Sci
, vol.106
, pp. 270-278
-
-
Tsukigawa, K.1
Liao, L.2
Nakamura, H.3
-
9
-
-
77954837315
-
In vitro and in vivo evaluation of tumor targeting styrene-maleic acid copolymer-pirarubicin micelles: survival improvement and inhibition of liver metastases
-
COI: 1:CAS:528:DC%2BC3cXhtVCktbjM, PID: 20579075
-
Daruwalla J, Nikfarjam M, Greish K et al (2010) In vitro and in vivo evaluation of tumor targeting styrene-maleic acid copolymer-pirarubicin micelles: survival improvement and inhibition of liver metastases. Cancer Sci 101:1866–1874
-
(2010)
Cancer Sci
, vol.101
, pp. 1866-1874
-
-
Daruwalla, J.1
Nikfarjam, M.2
Greish, K.3
-
10
-
-
54449095986
-
Styrene maleic acid-pirarubicin disrupts tumor microcirculation and enhances the permeability of colorectal liver metastases
-
COI: 1:CAS:528:DC%2BD1MXltFSrtbg%3D, PID: 18953175
-
Daruwalla J, Greish K, Malcontenti-Wilson C et al (2009) Styrene maleic acid-pirarubicin disrupts tumor microcirculation and enhances the permeability of colorectal liver metastases. J Vasc Res 46:218–228
-
(2009)
J Vasc Res
, vol.46
, pp. 218-228
-
-
Daruwalla, J.1
Greish, K.2
Malcontenti-Wilson, C.3
-
11
-
-
84938700372
-
SMA-pirarubicin induces tumor-selective oxidative stress and decreases tumor hypoxia as possible treatment of colorectal cancer liver metastases
-
Daruwalla J, Greish K, Malcontenti-Wilson C, et al (2015) SMA-pirarubicin induces tumor-selective oxidative stress and decreases tumor hypoxia as possible treatment of colorectal cancer liver metastases. Surgery 158(1):236–47
-
(2015)
Surgery
, vol.158
, Issue.1
, pp. 236-247
-
-
Daruwalla, J.1
Greish, K.2
Malcontenti-Wilson, C.3
-
12
-
-
80054695837
-
Intracellular uptake and behavior of two types zinc protoporphyrin (ZnPP) micelles, SMA-ZnPP and PEG-ZnPP as anticancer agents; unique intracellular disintegration of SMA micelles
-
COI: 1:CAS:528:DC%2BC3MXhtlWmur%2FN, PID: 21600248
-
Nakamura H, Fang J, Gahininath B et al (2011) Intracellular uptake and behavior of two types zinc protoporphyrin (ZnPP) micelles, SMA-ZnPP and PEG-ZnPP as anticancer agents; unique intracellular disintegration of SMA micelles. J Control Release 155:367–375
-
(2011)
J Control Release
, vol.155
, pp. 367-375
-
-
Nakamura, H.1
Fang, J.2
Gahininath, B.3
-
13
-
-
0038051355
-
Pirarubicin is taken up by a uridine-transportable sodium-dependent concentrative nucleoside transporter in Ehrlich ascites carcinoma cells
-
COI: 1:CAS:528:DC%2BD3sXksFWms7c%3D, PID: 12679883
-
Nagai K, Nagasawa K, Ishimoto A et al (2003) Pirarubicin is taken up by a uridine-transportable sodium-dependent concentrative nucleoside transporter in Ehrlich ascites carcinoma cells. Cancer Chemother Pharmacol 51:512–518
-
(2003)
Cancer Chemother Pharmacol
, vol.51
, pp. 512-518
-
-
Nagai, K.1
Nagasawa, K.2
Ishimoto, A.3
-
14
-
-
42749106212
-
Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev 18(4):CD005247
-
Shelley M, Harrison C, Coles B, et al (2006) Chemotherapy for hormone-refractory prostate cancer. Cochrane Database Syst Rev 18(4):CD005247. doi:10.1002/14651858.CD005247.pub2
-
(2006)
doi:10.1002/14651858.CD005247.pub2
-
-
Shelley, M.1
Harrison, C.2
Coles, B.3
-
15
-
-
33747469939
-
Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care’s Genitourinary Cancer Disease Site Group
-
PID: 16670021
-
Winquist E, Waldron T, Berry S et al (2006) Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care’s Genitourinary Cancer Disease Site Group. BMC Cancer 6:112
-
(2006)
BMC Cancer
, vol.6
, pp. 112
-
-
Winquist, E.1
Waldron, T.2
Berry, S.3
-
16
-
-
0029062830
-
Epirubicin and medroxyprogesterone acetate versus estramustine phosphate in hormone-resistant prostatic cancer: a prospective randomized study
-
COI: 1:STN:280:DyaK2MzosFOitA%3D%3D, PID: 7656906
-
Anderstrom C, Eddeland A, Folmerz P et al (1995) Epirubicin and medroxyprogesterone acetate versus estramustine phosphate in hormone-resistant prostatic cancer: a prospective randomized study. Eur Urol 27:301–305
-
(1995)
Eur Urol
, vol.27
, pp. 301-305
-
-
Anderstrom, C.1
Eddeland, A.2
Folmerz, P.3
-
17
-
-
0026515856
-
Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil
-
COI: 1:STN:280:DyaK387nsVSksQ%3D%3D, PID: 1540881
-
Laurie JA, Hahn RG, Therneau TM et al (1992) Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil. Cancer 69:1440–1444
-
(1992)
Cancer
, vol.69
, pp. 1440-1444
-
-
Laurie, J.A.1
Hahn, R.G.2
Therneau, T.M.3
-
18
-
-
0021343919
-
Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer. A randomized Southwest Oncology Group study
-
COI: 1:STN:280:DyaL2c7gs1agsg%3D%3D, PID: 6362815
-
Stephens RL, Vaughn C, Lane M et al (1984) Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer. A randomized Southwest Oncology Group study. Cancer 53:406–410
-
(1984)
Cancer
, vol.53
, pp. 406-410
-
-
Stephens, R.L.1
Vaughn, C.2
Lane, M.3
-
19
-
-
4744337716
-
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
-
COI: 1:CAS:528:DC%2BD2cXot1Kmu7c%3D, PID: 15470214
-
Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520
-
(2004)
N Engl J Med
, vol.351
, pp. 1513-1520
-
-
Petrylak, D.P.1
Tangen, C.M.2
Hussain, M.H.3
-
20
-
-
38349167518
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study
-
COI: 1:CAS:528:DC%2BD1cXitVWitLs%3D, PID: 18182665
-
Berthold DR, Pond GR, Soban F et al (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242–245
-
(2008)
J Clin Oncol
, vol.26
, pp. 242-245
-
-
Berthold, D.R.1
Pond, G.R.2
Soban, F.3
-
21
-
-
84869496799
-
Macromolecular therapeutics in cancer treatment: the EPR effect and beyond
-
COI: 1:CAS:528:DC%2BC38XnsFOquro%3D, PID: 22595146
-
Maeda H (2012) Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release 164:138–144
-
(2012)
J Control Release
, vol.164
, pp. 138-144
-
-
Maeda, H.1
-
22
-
-
70649088695
-
Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application
-
COI: 1:CAS:528:DC%2BD1MXhsFOltrnE, PID: 19793083
-
Seki T, Fang J, Maeda H (2009) Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application. Cancer Sci 100:2426–2430
-
(2009)
Cancer Sci
, vol.100
, pp. 2426-2430
-
-
Seki, T.1
Fang, J.2
Maeda, H.3
-
23
-
-
84922674063
-
Hormone and radiotherapy versus hormone or radiotherapy alone for non-metastatic prostate cancer: a systematic review with meta-analyses
-
COI: 1:STN:280:DC%2BC2cblslGktQ%3D%3D
-
Schmidt-Hansen M, Hoskin P, Kirkbride P et al (2014) Hormone and radiotherapy versus hormone or radiotherapy alone for non-metastatic prostate cancer: a systematic review with meta-analyses. Clin Oncol (R Coll Radiol) 26:e21–e46. doi:10.1016/j.clon.2014.06.016
-
(2014)
Clin Oncol (R Coll Radiol)
, vol.26
, pp. 21-46
-
-
Schmidt-Hansen, M.1
Hoskin, P.2
Kirkbride, P.3
-
24
-
-
79952999153
-
The potential benefit of radiotherapy with protons in head and neck cancer with respect to normal tissue sparing: a systematic review of literature
-
PID: 21349950
-
van de Water TA, Bijl HP, Schilstra C et al (2011) The potential benefit of radiotherapy with protons in head and neck cancer with respect to normal tissue sparing: a systematic review of literature. Oncologist 16:366–377
-
(2011)
Oncologist
, vol.16
, pp. 366-377
-
-
van de Water, T.A.1
Bijl, H.P.2
Schilstra, C.3
-
25
-
-
83955164302
-
Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis
-
PID: 21470787
-
Coen JJ, Zietman AL, Rossi CJ et al (2012) Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis. Int J Radiat Oncol Biol Phys 82:e25–e31
-
(2012)
Int J Radiat Oncol Biol Phys
, vol.82
, pp. 25-31
-
-
Coen, J.J.1
Zietman, A.L.2
Rossi, C.J.3
-
26
-
-
84940956193
-
Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity
-
PID: 25579058
-
Maeda H (2015) Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev. doi:10.1016/j.addr.2015.01.002
-
(2015)
Adv Drug Deliv Rev
-
-
Maeda, H.1
-
27
-
-
84977865921
-
Photodynamic therapy based on tumor-targeted polymer-conjugated zinc protoporphyrin and irradiation with xenon light
-
Fang J, Liao L, Yin H, et al (2015) Photodynamic therapy based on tumor-targeted polymer-conjugated zinc protoporphyrin and irradiation with xenon light. Future Science OA FSO4. http://www.future-science.com/doi/pdf/10.4155/fso.15.2.
-
(2015)
Future Science OA FSO4
-
-
Fang, J.1
Liao, L.2
Yin, H.3
-
28
-
-
75749149269
-
HPMA copolymers: origins, early developments, present, and future
-
COI: 1:CAS:528:DC%2BC3cXhs1arsbg%3D, PID: 19919846
-
Kopecek J, Kopecková P (2010) HPMA copolymers: origins, early developments, present, and future. Adv Drug Deliv Rev 62:122–149
-
(2010)
Adv Drug Deliv Rev
, vol.62
, pp. 122-149
-
-
Kopecek, J.1
Kopecková, P.2
-
29
-
-
75749144204
-
Structural and chemical aspects of HPMA copolymers as drug carriers
-
COI: 1:CAS:528:DC%2BC3cXhs1arsbk%3D, PID: 19931329
-
Ulbrich K, Subr V (2010) Structural and chemical aspects of HPMA copolymers as drug carriers. Adv Drug Deliv Rev 62:150–166
-
(2010)
Adv Drug Deliv Rev
, vol.62
, pp. 150-166
-
-
Ulbrich, K.1
Subr, V.2
|